IQVIA (NYSE:IQV) Earns Buy Rating from Truist Financial

IQVIA (NYSE:IQV)‘s stock had its “buy” rating reiterated by Truist Financial in a research note issued on Monday,Benzinga reports. They presently have a $263.00 price target on the medical research company’s stock, up from their prior price target of $261.00. Truist Financial’s price target indicates a potential upside of 30.88% from the stock’s current price.

IQV has been the topic of several other reports. TD Cowen cut their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Barclays reduced their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Trading Down 2.9 %

IQVIA stock opened at $200.94 on Monday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The firm’s 50-day moving average is $200.77 and its 200-day moving average is $219.09. The company has a market cap of $36.47 billion, a P/E ratio of 26.79, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts expect that IQVIA will post 10.81 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $236,120,000. American Century Companies Inc. lifted its position in IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after buying an additional 905,960 shares in the last quarter. FMR LLC grew its holdings in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of IQVIA in the third quarter worth $147,683,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.